OmniComm and MediStat Expand Presence in Israel


OmniComm to Deliver Keynote Address at MediStat’s February EDC Event in Tel Aviv

Fort Lauderdale, FL - In the past year, the Israeli life sciences sector has undergone notable changes, including a new partnership between OmniComm Systems, Inc., a global leading provider of clinical data management technology, and MediStat Ltd., a leading data management and biostatistics organization, headquartered in Tel Aviv, Israel. Under an agreement between the two companies, OmniComm’s TrialMaster electronic data capture (EDC) suite will be used to fulfill the clinical trials needs of the growing Israeli life sciences sector, which includes more than 1,300 organizations.

"We are truly excited to be part of the growing EDC market in Israel and worldwide. Being a partner with OmniComm is the main reason we are able to deliver successful intelligent EDC solutions to our customers," said Dr. Gil Harari, president and CEO of MediStat.

The pact between the two companies has already produced results, with several leading life sciences companies in Israel selecting TrialMaster EDC for their clinical research. Additionally, representatives from OmniComm will deliver presentations at MediStat’s Intelligent EDC Solutions Forum on February 6, 2017 in Tel Aviv.

The event will feature presentations from industry thought leaders on a variety of topics:

  • Managing randomization and drug supply with EDC.

  • Risk-based monitoring.

  • Modern issues and methods in biostatistics.

  • Integration of ad-hoc reporting with EDC.

  • Implementing a successful EDC solution.

Executives at MediStat selected TrialMaster EDC, because they needed a versatile and easy-to-use, design and build toolset that enables faster study build times. Moreover, the selection of TrialMaster was based on several additional factors, including TrialMaster’s reputation for flexibility, scalability, data quality and broad capabilities. Those criteria were especially important to MediStat, which supports the needs of the burgeoning pharmaceutical and biotechnology industry in Israel.

“MediStat is seeing strong demand for OmniComm’s TrialMaster EDC in Israel and is able to expand the capabilities offered to its customers,” said Kuno van der Post, senior vice president of business development, OmniComm Systems. “The timing is perfect to establish a presence in the region, with increasing demand from our existing multinational clients, who are seeking to uncover market opportunities in high-growth economies. Finding a partner like MediStat, with its experience and deep knowledge of clinical studies, coupled with its familiarity with the local culture, language and perspective, will be vital to our regional growth. Over the next year, we expect MediStat to expand its regional presence and capture a significant share of the growing clinical trials market in Israel.”

Supporting ReferencesOmniComm Systems Penetrates Growing Israeli Life Sciences MarketTrialMaster EDC Rated #1 by Clinical Research Sites SurveyedAbout MediStat
MediStat Ltd. specializes in biostatistics and data management, operating since 1995. It provides a wide range of related services to clients that conduct and manage biomedical research. The core services of MediStat are clinical trials data management and biostatistical analysis. MediStat is committed to providing all its clients with comprehensive solutions for planning, managing, and analyzing their clinical trials. For more information, visit

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 5,000 clinical trials. For more information, visit

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
© 2023 MJH Life Sciences

All rights reserved.